➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
AstraZeneca
McKinsey
McKesson
Boehringer Ingelheim

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,549,999

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,549,999 protect, and when does it expire?

Patent 9,549,999 protects MYOVIEW 30ML and is included in one NDA.

This patent has eight patent family members in seven countries.

Summary for Patent: 9,549,999
Title:Radiopharmaceutical composition
Abstract: The present invention provides a .sup.99mTc-tetrofosmin radiopharmaceutical composition comprising tetrofosmin and a radioprotectant at a particular range of molar ratios. A kit and a multi-dose kit for the preparation of the radiopharmaceutical composition of the invention are also provided, as well as a process for the preparation of multiple unit patient doses of the radiopharmaceutical composition and a unit dose of the radiopharmaceutical composition.
Inventor(s): Veggeland; Janne (Oslo, NO), Madsen; Grethe Karin (Oslo, NO), Hemsted; Stig (Oslo, NO)
Assignee: GE Healthcare Limited (GB)
Application Number:12/677,528
Patent Claim Types:
see list of patent claims
Composition; Formulation; Process;

Drugs Protected by US Patent 9,549,999

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ge Healthcare MYOVIEW 30ML technetium tc-99m tetrofosmin kit INJECTABLE;INJECTION 020372-002 Jul 7, 2005 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,549,999

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0718386.6Sep 21, 2007
PCT Information
PCT FiledSeptember 19, 2008PCT Application Number:PCT/EP2008/062528
PCT Publication Date:March 26, 2009PCT Publication Number: WO2009/037336

International Family Members for US Patent 9,549,999

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 101861170   Start Trial
European Patent Office 2190484   Start Trial
Spain 2562441   Start Trial
United Kingdom 0718386   Start Trial
Hong Kong 1149203   Start Trial
Japan 2010539222   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Harvard Business School
Baxter
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.